ProofPilot Acquires Lokavant to Enhance Clinical Trial Analytics
ProofPilot has acquired Lokavant, a leader in clinical trial intelligence, to integrate predictive analytics into its platform, announced in a press release. This acquisition aims to combine ProofPilot's trial execution capabilities with Lokavant's advanced analytics, offering a comprehensive solution for optimizing clinical research.
Lokavant, spun out of Roivant in 2020, uses historical and real-time data to provide predictive insights and improve study feasibility. By integrating these capabilities, ProofPilot enhances its platform, allowing sponsors and CROs to anticipate challenges and drive faster, more reliable outcomes.
The combined platform offers AI-powered study forecasting, real-time performance dashboards, and enhanced study oversight capabilities. This integration is designed to improve operational predictability, reduce risk, and ensure trials generate reliable results, ultimately accelerating the delivery of new therapies to patients.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more